

## AT A GLANCE

NASDAQ: GILD  
 Founded: 1987  
 HQ: Foster City, CA

**\$88.95B**  
 Market Cap  
 (as of 10/25/2018)



~**11,000**  
 Employees



Presence in  
**>35** Countries  
 across  
**6** Continents



**4** Primary Therapeutic  
 Areas of Focus:

- HIV
- Liver Disease
- Oncology
- Inflammation

### 3Q18 FINANCIALS

#### PRODUCT REVENUE

**\$5.5B**

#### NON-GAAP EPS

**\$1.84**

#### OPERATING CASH FLOW

**\$2.2B**

### SELECTED PIPELINE PRODUCT CANDIDATES

	Phase 1	Phase 2	Phase 3
<b>HIV</b>			
<b>Descovy</b> Potential Indications: PrEP	[Progress bar: Phase 1 to Phase 3]		
<b>Liver Diseases</b>			
<b>Selonsertib</b> Potential Indication: NASH	[Progress bar: Phase 1 to Phase 3]		
<b>GS-9674</b> Potential Indications: NASH, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis	[Progress bar: Phase 1 to Phase 2]		
<b>GS-0976</b> Potential Indication: NASH	[Progress bar: Phase 1 to Phase 2]		
<b>Hematology / Oncology</b>			
<b>Yescarta (axicabtagene ciloleucel)</b> Potential Indication: Indolent NHL	[Progress bar: Phase 1 to Phase 3]		
Potential Indication: DLBCL (in combination with PD-L1 mAb)	[Progress bar: Phase 1 to Phase 2]		
Potential Indication: 2nd Line DLBCL	[Progress bar: Phase 1 to Phase 3]		
<b>KTE-X19</b> Potential Indication: MCL	[Progress bar: Phase 1 to Phase 2]		
Potential Indication: Adult ALL	[Progress bar: Phase 1 to Phase 2]		
Potential Indication: Pediatric ALL	[Progress bar: Phase 1 to Phase 2]		
<b>KITE-585 (anti-BCMA)</b> Potential Indication: MM	[Progress bar: Phase 1 to Phase 2]		
<b>KITE-718 (MAGE A3/A6)</b> Potential Indication: Solid Tumor	[Progress bar: Phase 1 to Phase 2]		
<b>Inflammation / Respiratory</b>			
<b>Filgotinib</b> Potential Indications: Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis	[Progress bar: Phase 1 to Phase 3]		
Potential Indications: Inflammatory Diseases	[Progress bar: Phase 1 to Phase 2]		

### COMMERCIAL PORTFOLIO HIGHLIGHTS

#### Human Immunodeficiency Virus (HIV)

Treatment:



Prevention:



#### Hepatitis C Virus (HCV)



#### Hepatitis B Virus (HBV)



#### Hematology / Oncology



### ANALYST COVERAGE

Argus, Atlantic Equities, Baird, BofA Merrill Lynch, Barclays, Cantor Fitzgerald, Citi, Cowen & Company, Evercore ISI, Goldman Sachs, Jefferies, JPMorgan, Leerink Partners, Maxim Group, Mizuho, Morgan Stanley, Morningstar, Needham, Oppenheimer, Piper Jaffray, Raymond James, RBC, Standard and Poors, UBS, Wells Fargo